BENEFIT-RISK ANALYSIS OF ADALIMUMAB AND ALTERNATIVE TREATMENTS FOR MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS

被引：0
|
作者：
Hicks, K. A. [1 ]
Earnshaw, S. R. [1 ]
Shaw, J. W. [2 ]
Cifaldi, M. [2 ]
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.1360
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A439 / A440
页数：2
相关论文
共 50 条
  • [1] Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
    Conaghan, Philip
    Cohen, Stanley
    Burmester, Gerd
    Mysler, Eduardo
    Nash, Peter
    Tanaka, Yoshiya
    Rigby, William
    Patel, Jayeshkumar
    Shaw, Tim
    Betts, Keith A.
    Patel, Pankaj
    Liu, Jianzhong
    Sun, Rochelle
    Fleischmann, Roy
    RHEUMATOLOGY AND THERAPY, 2022, 9 (01) : 191 - 206
  • [2] Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
    Philip Conaghan
    Stanley Cohen
    Gerd Burmester
    Eduardo Mysler
    Peter Nash
    Yoshiya Tanaka
    William Rigby
    Jayeshkumar Patel
    Tim Shaw
    Keith A. Betts
    Pankaj Patel
    Jianzhong Liu
    Rochelle Sun
    Roy Fleischmann
    Rheumatology and Therapy, 2022, 9 : 191 - 206
  • [3] Multimethod quantitative benefit-risk assessment of treatments for moderate-to-severe osteoarthritis
    Mauer, Jonathan
    Bullok, Kristin
    Watt, Stephen
    Whalen, Ed
    Russo, Leo
    Junor, Rod
    Markman, John
    Hauber, Brett
    Tervonen, Tommi
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (08) : 3837 - 3846
  • [4] Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective
    M. Elaine Husni
    Keith A. Betts
    Jenny Griffith
    Yan Song
    Arijit Ganguli
    Rheumatology International, 2017, 37 : 1423 - 1434
  • [5] Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective
    Husni, M. Elaine
    Betts, Keith A.
    Griffith, Jenny
    Song, Yan
    Ganguli, Arijit
    RHEUMATOLOGY INTERNATIONAL, 2017, 37 (09) : 1423 - 1434
  • [6] Thresholds of Benefit-Risk Trade-Offs from the Patient Perspective for Treatment Decisions in Moderate-to-Severe Rheumatoid Arthritis
    Husni, M. Elaine
    Griffith, Jenny
    Betts, Keith
    Song, Yan
    Ganguli, Arijit
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [7] Rheumatologists' Benefit-Risk Preferences for Biologic Treatments for Rheumatoid Arthritis
    Hauber, A. Brett
    Cross, James T.
    Yocum, David E.
    Johnson, F. Reed
    Yang, Jui-Chen
    Villaneuva, Isidro
    Katz, Patricia P.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S487 - S488
  • [8] Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
    Armstrong, April W.
    Soliman, Ahmed M.
    Betts, Keith A.
    Wang, Yan
    Gao, Yawen
    Stakias, Vassilis
    Puig, Luis
    DERMATOLOGY AND THERAPY, 2022, 12 (01) : 167 - 184
  • [9] Comparison of benefit-risk profiles for adalimumab, methotrexate, and placebo in the treatment of moderate to severe psoriasis
    Papp, Kim
    Signorovitch, James
    Mulani, Parvez
    Bao, Yanjun
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (03) : AB126 - AB126
  • [10] Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan
    Chen, Der-Yuan
    Hsu, Ping-Ning
    Tang, Chao-Hsiun
    Claxton, Lindsay
    Valluri, Satish
    Gerber, Robert A.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (08) : 777 - 787
12345